Last updated: 2026-10-13 09:19:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Bionano Genomics, Inc. (BNGO) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NASDAQ. The stock is currently priced at $1.35, with a market capitalisation of $16.90M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.00 to $2.23. This page covers its latest market performance, valuation, price trends and company information.
$16.90M | |
$1.35 | |
$9,414.00 | |
$1.00 | |
$1.35 | |
22.00 | |
940.56K | |
-- | |
$2.23 | |
$1.00 | |
-- | |
-- |
Bionano Genomics, Inc. (BNGO) is trading at $1.35 in pre-market trading as of 2026-10-13 08:01:00, up 0.37% ($0.01) from the previous close of $1.35
Pre-market trading shows how investors are pricing BNGO before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Bionano Genomics, Inc. (BNGO) moved from $1.48 to $1.35, representing a decline of 8.78% ($0.13).
The stock traded between $1.29 and $1.62 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 264.22 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 28.5%
BNGO is currently trading at $1.35, placing it 28.5% of the way from its 52-week low of $1.00 to its 52-week high of $2.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 97 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Bionano Genomics, Inc. (BNGO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.